CelLBxHealth PLC - Board changes - Replacement
GENERAL TEXT AMENDMENT
The following amendment has been made to the 'Board changes' announcement released on
Addition of "Klaas De Boer holds an interest in 2,002,319 ordinary shares in CelLBxHealth plc which represents an approximately 0.18% holding of the Company's issued share capital."
All other details remain unchanged.
The full amended text is shown below.
CelLBxHealth plc (the "Company")
Board changes
·
· Klaas de Boer as Non-Executive Director
·
·
The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.
Separately Non-Executive Director,
For further information:
|
CelLBxHealth plc |
+44 (0) 1483 343434 |
|
Cavendish (NOMAD and Broker) |
+44 (0) 20 7220 0500 |
|
FTI Consulting Simon |
+44 (0) 203 727 1000 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of
About CelLBxHealth plc
CelLBxHealth plc is a leading CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.
The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified
For more information, visit https://cellbxhealth.com/.
AIM Rules Schedule 2 (g) information
The directorships and partnerships currently held by
|
Current directorships |
Previous directorships held in the past five years |
||
|
|
|
The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:
|
Current directorships |
Previous directorships held in the past five years |
|
Tsjukemar Ltd General Fusion Inc Xeros Technology Group plc SmartKem Inc Smartkem Ltd Fashion for Good BV |
Entrepreneurs Fund Management LLP Entrepreneurs Fund Management Services Ltd veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH) Stichting Administratiekantoor Bellevue
|
Klaas De Boer holds an interest in 2,002,319 ordinary shares in CelLBxHealth plc which represents an approximately 0.18% holding of the Company's issued share capital.
The directorships and partnerships currently held by
|
Current directorships |
Previous directorships held in the past five years |
|
|
Applied Technology Partners LLC |
The directorships and partnerships currently held by
|
Current directorships |
Previous directorships held in the past five years |
||
|
|
There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE